MedTrace Logo

Pain Management in Response to Exparel vs. Standard Bupivicaine

NCT02499159 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-02-16

Study results available
· View outcomes & findings →

Summary

This study is looking to evaluate the efficacy of liposomal bupivicaine (Exparel) on decreasing the amount of consumed pain medications.

Patients will be randomly selected to received either Exparel or standard bupivicaine injection during surgery. Patients will be followed up to assess pain levels using a visual pain scale, and to assess how much pain medication was consumed.

Conditions

Interventions

DRUG

Liposomal Bupivicaine

266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.

DRUG

0.25% standard bupivicaine

standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.

Sponsors & Collaborators

  • Mednax National Medical Group

    collaborator UNKNOWN

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Sandeep J Khandhar, MD · Cardiac, Vascular, and Thoracic Surgery Associates

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499159 on ClinicalTrials.gov